Is Psychedelic Assisted Therapy Right For Your Patients?

Referral Form

It could be appropriate for your patient if they meet the following requirements:

●  Diagnosis of a treatment-resistant mental health condition, such as:

○  Major Depressive Disorder (MDD)

○  Post-Traumatic Stress Disorder (PTSD)

○  Generalized Anxiety Disorder (GAD)

○  Obsessive-Compulsive Disorder (OCD)

○  Bipolar Depression

●  Inadequate response to at least two evidence-based treatments, such as:

○  Two or more antidepressant medications, OR

○  One medication and one structured psychotherapy (e.g. CBT, DBT), OR

○  Two structured therapy modalities

●  Must be under the care of a psychiatrist or physician who can provide a referral.

●  Age 18 or older

It is not appropriate for your patient if they have:

●  Uncontrolled medical conditions, such as high blood pressure or heart disease

●  Current substance use disorder (excluding nicotine or caffeine)

●  History of psychosis, schizophrenia, active mania or bipolar

●  Pregnancy or breastfeeding

●  Active suicidal ideation with a plan or recent suicide attempt (requires stabilization first)

●  Unstable psychiatric conditions that require acute inpatient care

Treatment Results

Table summarizing mental health screening results, including cohorts, number of people screened positive, clinical improvements, and scores for generalized anxiety disorder, depression, post-traumatic stress disorder, and life work functionality.

Source: Roots to Thrive. Cohort 1, 2, and 3 Combined Quantitative Results. The enclosed data includes the participants who screened positive for PTSD, depression, or generalized anxiety disorder upon entry into the RTI-KAT program. The pre-results were taken within 1 month of the program beginning and post-results were taken directly after the 12-week program was completed. If data was missing, it was not included.

Current Evidence

Major Depressive Disorder (MDD)

Associated with significant reduction of depression severity and improvement in depressive symptoms starting within 2 hours after administration until day 14.

Bipolar Depression

Possibly linked with significant improvement of depressive symptoms in individuals with treatment-resistant bipolar depression which continued for 3 days.

Post Traumatic Stress Disorder (PTSD)

Reported significant reduction in severity of PTSD when assessed 24 hours post-infusion.

Source: CPSA Indications of use for Ketamine—Clinical Toolkit